1. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В., Карпов Ю.А., Архипов М.В., Барбараш О.Л., Галявич А.С., Гринштейн Ю.И., Ерегин С.Я., Карпов Р.С. и др. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологический вестник. 2015. № 1. С. 3-30.
2. Глобальное резюме по гипертонии. ВОЗ, 2013. 40 с.
3. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005. V. 365. P. 217-223.
4. Irazola V.E., Gutierrez L., Bloomfield G., Carrillo-Larco R.M., Dorairaj P., Gaziano T., Levitt N.S., Miranda J.J., Ortiz A.B., Steyn K., Wu Y., Xavier D., Yan L.L., He J., Rubinstein A. Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global Heart. 2016. V. 11. № 1. P. 47-59.
5. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Конради А.О. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечениеи контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014. Т. 13. № 4. С. 4-14.
6. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S.C., White I.R., Caulfield M.J., Deanfield J.E., Smeeth L., Williams B.P., Hingorani A.D., Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. The Lancet. 2014. V. 383. № 9932. P. 1899-1911.
7. Ehret G.B. Genome-Wide Association Studies: Contribution of Genomics to Understanding Blood Pressure and Essential Hypertension. Current Hypertension Reports. 2010. V. 12. № 1. P. 17-25.
8. Shih P.B., O’Connor D.T. Hereditary Determinants of Human Hypertension. Strategies in the Setting of Genetic Complexity. Hypertension. 2008. V. 51. № 6. P. 1456-1464.
9. Cornelissen V.A., Fagard R.H., Coeckelberghs E., Vanhees L. Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors A Meta-Analysis of Randomized, Controlled Trials. Hypertension. 2011. V. 58. № 5. P. 950-958.
10. Система кровообращения и артериальная гипертония: биофизические и генетико-физиологические механизмы, математическое и компьютерное моделирование. Под ред. Ивановой Л.Н., Блохина А.М., Маркель А.Л. Новосибирск: Издательство СО РАН, 2008. 252 с.
11. Oparil S., Acelajado M.C., Bakris G.L., Berlowitz D.R., Cífková R., Dominiczak A.F., Grassi G., Jordan J., Poulter N.R., Rodgers A., Whelton P.K. Hypertension. Nature Reviews Disease Primers. 2018. V. 4. P. 18014.
12. Campbell N.R., Lackland D.T., Niebylski M.L. High blood pressure: why prevention and control are urgent and important: a 2014 fact sheet from the World Hypertension League and the International Society of Hypertension. The Journal of Clinical Hypertension. 2014. V. 16. № 8. P. 551-553.
13. Лебедев А.А. Система ренин - ангиотензин. Соросовский образовательный журнал. 1998. № 3. С. 35-40.
14. Sethi A.A., Nordestgaard B.G., Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a metaanalysis. Arterioscler. Tromb. Vasc. Biol. 2003. V. 7. № 23. P. 1269-1275.
15. Киселев И.Н., Семисалов Б.В., Бибердорф Э.А., Шарипов Р.Н., Блохин А.М., Колпаков Ф.А. Модульное моделирование сердечно-сосудистой системы человека. Математическая биология и биоинформатика. 2012. Т. 7. № 2. С. 703-736. doi: 10.17537/2012.7.703.
16. Киселев И.Н., Бибердорф Э.А., Баранов В.И., Комлягина Т.Г., Мельников В.Н., Суворова И.Ю., Кривощеков С.Г., Колпаков Ф.А. Персонализация параметров и валидация модели сердечно-сосудистой системы человека. Математическая биология и биоинформатика. 2015. Т. 10. № 2. С. 526-547. doi: 10.17537/2015.10.526.
17. Колпакова А.Ф. О возможностях применения прямого ингибитора ренина алискирена для лечения социально значимых заболеваний. Сибирский медицинский журнал. 2014. Т. 29. № 2. С. 14-21.
18. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005. V. 111. P. 1012-1018.
19. Sica D.A., Gehr T.W., Ghosh S. Clinical Pharmacokinetics of Losartan. Clinical Pharmacokinetics. 2005. V. 44. № 8. P. 797-814.
20. Steinmann E., Pfisterer M., Burkart F. Acute hemodynamic effects of bisoprolol, a new beta 1 selective adrenoreceptor blocking agent, in patients with coronary artery disease. Journal of Cardiovascular Pharmacology. 1986. V. 8. № 5. P. 1044-1050.
21. Ferguson R.K., Vlasses P.H., Swanson B.N., Mojaverian P., Hichens M., Irvin J.D., Huber P.B. Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clinical Pharmacology and Therapeutics. 1982. V. 32. № 1. P. 48-53.
22. Faulkner J.K., McGibney D., Chasseaud L.F., Perry J.L., Taylor I.W. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. British Journal of Clinical Pharmacology. 1986. V. 22. P. 21-25.
23. Прошин А.П., Солодянников Ю.В. Математическое моделирование системы кровообращения и его практические применения. Автоматика и телемеханика. 2006. № 2. 174-188.
24. Karaaslan F., Denizhan Y., Kayserilioglu A., Ozcan Gulcur H. Long-term mathematical model involving renal sympathetic nerve activity, arterial pressure, and sodium excretion. Annals of Biomedical Engineering. 2005. V. 33. № 11. P. 1607-1630.
25. Hallow K.M., Lo A., Beh J., Rodrigo M., Ermakov S., Friedman S., de Leon H., Sarkar A., Xiong Y., Sarangapani R., Schmidt H., Webb R., Kondic A.G. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: Extending the Guyton model. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2014. V. 306. № 9. P. R647-R662.
26. Hindmarsh A.C., Brown P.N., Grant K.E., Lee S.L., Serban R., Shumaker, D.E., Woodward C.S. SUNDIALS: Suite of Nonlinear and Differential/Algebraic Equation Solvers. ACM Transactions on Mathematical Software. 2005. V. 31. № 3. P. 363-396.
27. Hong Y., Dingemanse J., Mager D.E. Pharmacokinetic/Pharmacodynamics modeling of renin biomarkers in subjects treated with the renin inhibitor Aliskiren. Clinical Pharmacology Therapeutics. 2008. V. 84. № 1. P. 136-143.
28. Bonate P.L. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2006. 387 p.
29. Интенсивная терапия. Национальное руководство. Т. 2. Под ред. Гельфанда Б.Р., Салтанова А.И. Москва: ГЭОТАР-Медиа, 2011.
30. Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews. 2008. V. 4. Article No. CD003822.
31. Lithell H., Selinus I., Hosie J., Frithz G., Weiner L. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. European Heart Journal. 1987. V. 8. P. 55-64.
32. Hayashi K., Wakino S., Sugano N., Ozawa Y., Homma K., Saruta T. Ca2+ Channel Subtypes and Pharmacology in the Kidney. Circulation Research. 2007. V. 100. № 3. P. 342-353.
33. Мельников В.Н., Комлягина Т.Г., Речкина С.Ю., Лазарева И.Ф., Суворова И.Ю., Кривощеков С.Г. Показатели эластичности артерий и гемодинамики у здоровых и больных людей: база данных, зарегистрирована в Реестре баз данных Федеральной службы по интеллектуальной собственности 9 июня 2012 г. № 2012620540.
34. Pruett W.A., Husband L.D., Husband G., Dakhlalla M., Bellamy K., Coleman T.G., Hester R.L. A population Model of Integrative Cardiovascular physiology. PLoS One. 2013. V. 8. № 9.
35. Киселев И.Н., Шарипов Р.Н., Мандрик Н.В., Колпаков Ф.А. Популяционное моделирование сердечно-сосудистой системы человека в платформе BioUML. В: Труды XVI Всероссийской конференции DICR-2017. Новосибирск, 2017 г. С. 212-217.
36. Gibson J.G., Evans W.A. Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in NINETY normal humans. The Journal of Clinical Investigation. 1937. V. 16. № 3. P. 317-328.
37. Терегулов Ю.Э. Интегральные показатели центральной гемодинамики у здоровых лиц и пациентов с гипертонической болезнью в зависимости от типа гемодинамики. Практическая медицина. 2012. Т. 2. № 8(64). С. 164-168.
38. Казакова М.С., Луговская С.А., Долгов В.В. Референсные значения показателей общего анализа крови взрослого работающего населения. Клиническая лабораторная диагностика. 2012. № 6. С. 43-49.
39. Payne R.B., Levell M.J. Redefinition of the normal range for serum sodium. Clinical Chemistry. 1968. V. 14. № 2. P. 172-178.
40. Rastegar A. Chapter 195. Serum Potassium. In: Clinical methods: The history, physical, and laboratory examinations. 3rd edition. Eds. Walker H.K., Hall W.D., Hurst J.W. Boston: Butterworths, 1990.
41. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А.М. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012. Т. 16. № 1. С. 89-115.
42. Bertram J.F., Douglas-Denton R.N., Diouf B., Hughson M.D., Hoy W.E. Human nephron number: implications for health and disease. Pediatric Nephrology. 2011. V. 26. P. 1529-1533.
43. Hoy W.E., Ingelfinger J.R., Hallan S., Hughson M.D., Mott S.A., Bertram J.F. The early development of the kidney and implications for future health. Journal of Developmental Origins of Health and Disease. 2010. V. 1. № 4. P. 216-233.
44. Hoy W.E., Douglas-Denton R.N., Hughson M.D., Cass A., Johnson K., Bertram J.F. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney International Supplements. 2003. V. 63. № 83. P. S31-S37.
45. Nozuki M., Mouri T., Itoi K., Takahashi K., Totsune K., Saito T., Yoshinaga K. Plasma concentrations of atrial natriuretic peptide in various diseases. The Tohoku Journal of Experimental Medicine. 1986. V. 148. P. 439-447.
46. Рекомендации по количественной оценке структуры и функции камер сердца. Под ред. Васюка Ю.А. Приложение 1 к Российскому кардиологическому журналу. 2012. Т. 3. № 95. С. 1-28.
47. Hudsmith L.E., Petersen S.E., Francis J.M., Robson M.D., Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance. 2005. V. 7. P. 775-782.
48. Мельник А.А. Определение уровней активного ренина и альдостерона в крови для персонализации лечения артериальной гипертензии. Медицинская газета «3доровье Украины». 2017. № 19 (416).
49. Valabhji J., Donovan J., Kyd P.A., Schachter M., Elkeles R.S. The relationship between active renin concentration and plasma renin activity in Type 1 diabetes. Diabetic Medicine. 2001. V. 18. P. 451-458.
50. Nussberger J., Brunner D., Keller I., Brunner H.R. Measurement of converting enzyme activity by antibody-trapping of generatedangiotensin II. Comparison with two other methods. American Journal of Hypertension. 1992. V. 5. P. 393-398.
51. Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С., Талалаева Т.Г., Хорева С.Н. Роль и целевой уровень отдельных компонентов ренин-ангиотензин-альдостероновой системы в развитии сердечно-сосудистых осложнений у больных артериальной гипертензией. Российский кардиологический журнал. 2009. № 3 (77). С. 26-32.
52. Brown M.J., McInnes G.T., Papst C.C., Zhang J., MacDonald T.M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. The Lancet. 2011. V. 377. P. 312-320.
53. Kwakernaak A.J., Roksnoer L.C., Lambers Heerspink H.J., van den Berg-Garrelds I., Lochorn G.A., van Embden Andres J.H., Klijn M.A., Kobori H., Danser A.H., Laverman G.D., Navis G.J. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial. PLoS One. 2017. V. 12. № 1. Article No. e0169258.
54. Porthan K., Viitasalo M., Hiltunen T.P., Väänänen H., Dabek J., Suonsyrjä T., Hannila-Handelberg T., Virolainen J., Nieminen M.S., Toivonen L., Kontula K., Oikarinen L. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Annals of Medicine. 2009. V. 41. № 1. P. 29-37.
55. Nedogoda S.V., Ledyaeva A.A., Chumachok E.V., Tsoma V.V., Mazina G., Salasyuk A.S., Barykina I.N. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clinical Drug Investigation. 2013. V. 33. № 8. P. 553-561.
56. Oparil S., Barr E., Elkins M., Liss C., Vrecenak A., Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clinical Therapeutics. 1996. V. 18. № 4. P. 608-625.
57. Martina B., Dieterle T., Weinbacher M., Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology. 1999. V. 92. № 2. P. 110-114.
58. Lee S.E., Kim Y.J., Lee H.Y., Yang H.M., Park C.G., Kim J.J., Kim S.K., Rhee M.Y., Oh B.H. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clinical Therapeutics. 2012. V. 34. № 3. P. 552-568.
59. Oparil S., Abate N., Chen E., Creager M.A., Galet V., Jia G., Julius S., Lerman A., Lyle P.A., Pool J., Tershakovec A.M. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Current Medical Research and Opinion. 2008. V. 24. № 4. P. 1101-1114.
60. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Pressure. 2007. V. 16. № 2. P. 7-12.
61. Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. American Journal of Cardiology. 1991. V. 68. P. 61-64.
62. Amabile G., Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. European Heart Journal. 1987. V. 8. P. 65-69.
63. Honore P. Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study. European Heart Journal. 1987. V. 8. P. 95-102.
64. Mengden T., Bättig B., Schubert M., Jeck T., Weisser B., Buddeberg C., Vetter W. Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol. European Journal of Clinical Pharmacology. 1992. V. 42. № 6. P. 569-576.
65. Puig J.G., Calvo C., Luurila O., Luurila H., Sulosaari S., Strandberg A., Ghezzi C. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. Journal of Human Hypertension. 2007. V. 21. № 12. P. 917-924.
66. Mallion J.M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Pressure. 2007. V. 16. № 2. P. 13-18.
67. Agabiti Rosei E., Morelli P., Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Pressure. 2005. V. 14. № 1. P. 14-22.
68. Fagher B., Henningsen N., Hulthén L., Katzman P., Thulin T. Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. European Journal of Clinical Pharmacology. 1990. V. 39. № 1. P. S41-S43.
69. Fermé I., Djian J., Tcherdakoff P. Comparative study on monotherapy with sustained-release diltiazem 300 mg and enalapril 20 mg in mild to moderate arterial hypertension. Journal of Cardiovascular Pharmacology. 1990. V. 16. Suppl. 1. P. S46-S50.
70. Corea L., Cardoni O., Fogari R., Innocenti P., Porcellati C., Provvidenza M., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clinical Pharmacology and Therapeutics. 1996. V. 60. № 3. P. 341-346.
71. Tham T.C., Herity N., Guy S., Silke B. Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. British Journal of Pharmacology. 1993. V. 36. № 6. P. 555-560.
72. Parving H-H., Brenner B.M., McMurray J.V., Dick de Zeeuw, Steven M. Haffner, Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides M., Richard A., Xiang Z. et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. Engl. J. Med. 2012. V. 367. P. 2204-2213.
73. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat. Med. 2012. V. 18. № 3. P. 326.